4basebio PLC (LON:4BB - Get Free Report) insider Heikki Lanckriet purchased 46,500 shares of the stock in a transaction dated Friday, November 15th. The stock was bought at an average cost of GBX 1,325 ($16.80) per share, with a total value of £616,125 ($780,992.52).

4basebio stock traded down GBX 40 ($0.51) during trading hours on Tuesday, hitting GBX 1,260 ($15.97). The stock had a trading volume of 183 shares, compared to its average volume of 4,601. The stock's 50-day moving average price is GBX 1,346.45 and its 200-day moving average price is GBX 1,410.28. The stock has a market capitalization of £161.41 million, a P/E ratio of -1,615.38 and a beta of 1.09. 4basebio PLC has a 12-month low of GBX 500 ($6.34) and a 12-month high of GBX 1,820 ($23.07). The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47.

4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider 4basebio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4basebio wasn't on the list.

While 4basebio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.